Inflammatory Markers During Early Treatment of Seroconverters in a Randomized Placebo-Controlled Trial of PrEP (ANRS-IPERGAY)

Sylvain Chawki; Isabelle Charreau; Audrey Gabassi; Diane Carette; Eric Cua; Laurent Cotte; Gilles Pialoux; Claire Pintado; Laurence Meyer; Marie-Laure Chaix; Constance Delaugerre; Jean-Michel Molina

doi:10.1093/ofid/ofab085

Inflammatory Markers During Early Treatment of Seroconverters in a Randomized Placebo-Controlled Trial of PrEP (ANRS-IPERGAY)

Open Forum Infect Dis. 2021 Mar 20;8(3):ofab085. doi: 10.1093/ofid/ofab085. eCollection 2021 Mar.

Authors

Sylvain Chawki^{1

2}, Isabelle Charreau³, Audrey Gabassi^{1

2}, Diane Carette³, Eric Cua⁴, Laurent Cotte⁵, Gilles Pialoux⁶, Claire Pintado⁷, Laurence Meyer³, Marie-Laure Chaix^{1

2}, Constance Delaugerre^{1

2}, Jean-Michel Molina^{7

2}

Affiliations

¹ Department of Virology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
² INSERM U944, Paris University, Paris, France.
³ INSERM SC10-US19, Villejuif, France.
⁴ Maladies Infectieuses, Hôpital L'Archet, Nice, France.
⁵ Maladies Infectieuses, Hospices Civils de Lyon, Hôpital de la Croix-Rousse, Lyon, France.
⁶ Maladies Infectieuses, Hôpital Tenon, Assistance Publique Hôpitaux de Paris, Paris, France.
⁷ Maladies Infectieuses, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France.

Abstract

HIV-related inflammation is associated with poor outcomes. We describe inflammatory biomarkers in 17 participants in a pre-exposure prophylaxis trial who seroconverted with very early initiation of antiretroviral therapy. Inflammation peaked at the time of HIV infection and returned to baseline within 6-12 months. Starting antiretroviral therapy very early could help mitigate long-lasting HIV-related inflammation.

Keywords: CRP; D-dimers; HIV; IL6; PrEP; early antiretroviral therapy; sCD14.